Aptar Pharma (ATR) announced it has acquired the clinical trial materials manufacturing capabilities of Mod3 Pharma from SWK Holdings (SWKH). The acquisition enhances Aptar’s support for early-stage drug development by providing formulation, fill and finish services for Phase 1 and 2 clinical trials. Through the deal, Aptar Pharma will operate an FDA-inspected facility in Boonton, New Jersey, with an initial focus on orally inhaled nasal drug products. Financial terms were not disclosed.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATR: